| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/CCO.0000000000000164 |
| P698 | PubMed publication ID | 25611025 |
| P50 | author | James Chih-Hsin Yang | Q37840097 |
| Bin-Chi Liao | Q64226808 | ||
| P2093 | author name string | Chia-Chi Lin | |
| P2860 | cites work | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 94-101 | |
| P577 | publication date | 2015-03-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current Opinion in Oncology | Q1909046 |
| P1476 | title | Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer | |
| P478 | volume | 27 |
| Q42700419 | AZD9291-induced Acute Interstitial Lung Disease |
| Q48165470 | An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors |
| Q38832105 | Anti-EGFR Agents: Current Status, Forecasts and Future Directions. |
| Q64121966 | Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation |
| Q33744196 | Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors |
| Q89266805 | Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer |
| Q38868651 | Autophagy is not uniformly cytoprotective: a personalized medicine approach for autophagy inhibition as a therapeutic strategy in non-small cell lung cancer |
| Q37001902 | Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report |
| Q50862064 | Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors |
| Q34490460 | CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer |
| Q38868047 | Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer |
| Q36844350 | Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. |
| Q91995280 | Covalent Inhibition in Drug Discovery |
| Q92898855 | DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291 |
| Q53394177 | Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma |
| Q41213157 | Differential expression of bone morphogenetic protein 5 in human lung squamous cell carcinoma and adenocarcinoma. |
| Q100750039 | Importin 13 promotes NSCLC progression by mediating RFPL3 nuclear translocation and hTERT expression upregulation |
| Q49887882 | Kinase-targeted cancer therapies: progress, challenges and future directions |
| Q90619271 | Liquid chromatography-tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites |
| Q97531214 | Molecular Dynamics Analysis of Binding Sites of Epidermal Growth Factor Receptor Kinase Inhibitors |
| Q28079320 | Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence |
| Q38990576 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. |
| Q51673799 | Olmutinib: First Global Approval |
| Q28079689 | Osimertinib making a breakthrough in lung cancer targeted therapy |
| Q55230293 | Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non-Small Cell Lung Cancer. |
| Q27853311 | Osimertinib: First Global Approval |
| Q91600409 | Rab25-Mediated EGFR Recycling Causes Tumor Acquired Radioresistance |
| Q33594692 | Rational design of non-resistant targeted cancer therapies |
| Q47213006 | Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. |
| Q35987305 | The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs |
| Q37709481 | The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q54982443 | The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. |
| Q37669352 | Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context |
| Q48604114 | Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs |
| Q64077897 | Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability |
| Q37138970 | XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer |
Search more.